APG2575
Phase 1Small molecule
Ascentage Pharma Group Inc.APG2575 is one of 50 small molecule programs targeting Macroglobulinemia. It is currently in Phase 1.
1
Indications
2
Total Trials
0
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
67 competitors in Macroglobulinemia
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 3
Rituxan
RochePhase 2
Leukeran
Akero TherapeuticsPhase 3
Calquence
AstraZenecaPhase 2
Darzalex
Johnson & JohnsonPhase 2
Thalomid
Bristol-Myers SquibbPhase 2
Velcade
SShilpa Grover, MD, MPH
Phase 2
Gazyva
RochePhase 2
Jaypirca
Eli LillyPhase 2
Ninlaro
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for APG2575. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company